Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy

Molecular Partners AG announced a strategic pivot to focus on radiopharmaceuticals, with its lead candidate MP0712 (DLL3-targeting Radio-DARPin) advancing in Phase 1/2a trials for small cell lung cancer. The company will reduce its workforce by up to 44% (~55 positions) to streamline operations, with changes implemented by Q2 2027. Initial safety data for MP0712 will be presented in December 2026, with efficacy data expected in 2027. The company has CHF 57.5 million in cash, expected to fund operations into late 2027.